Prostate Cancer Discoveries Digest Welcome to your monthly summary of the notable research studies and developments that help provide greater insight into prostate cancer causes, treatments, outcomes, and survivorship. See all Newsletters Jump To Jump To Join the Email List Welcome to the February 2025 edition of ZERO's Prostate Cancer Discoveries Digest! The latest information on treatment, diagnostics, survivorship, and more has been pulled from the headlines and delivered to your inbox. To ensure you receive this monthly newsletter, be sure to mark ZERO Prostate Cancer as a safe sender in your preferred email client. ZERO Prostate Cancer does not endorse any particular article or finding that may be featured. Genetics & Genomics Moffitt Study Shows How Genomic Tests Could Help Treat Prostate Cancer More Effectively Researchers assessed the Decipher, Oncotype DX Genomic Prostate Score (GPS), and Prolaris genomic tests to understand how results can help patients and doctors make treatment decisions in the early stage setting. The review is part of a larger Department of Veterans Affairs project. » Full Article from Moffitt Cancer Center Diagnostics FDA Fast Tracks 64Cu-SAR-bisPSMA for Biochemically Recurrent Prostate Cancer A second FDA fast-track designation (FTD) was awarded to 64Cu-SAR-bisPSMA for PET imaging of prostate-specific membrane antigen (PSMA)-positive lesions in patients with biochemical recurrence (BCR) of prostate cancer following initial definitive therapy. This novel, advanced imaging led 48% of patients to modify their treatment plan based on the results. » Full Article from Urology Times Genetics & Genomics Classifying FOXA1 Alterations: Implications for Prostate Cancer Prognosis and Treatment Researchers have learned more about the FOXA1 mutation, its higher prevalence in Asian and Black patients, and the classification system's revelation that different FOXA1 mutations may lead to opposing clinical outcomes. » Full Article from UroToday Risk Association Between Prostatic Calculi and Prostate Cancer A new, retrospective study demonstrates an association between prostatic calculi (stones found in the prostate gland) and prostate cancer. » Full Article from ScienceDirect Treatment Vaccine Trials Ongoing in Locally Advanced Oligometastatic Prostate Cancer Prostate cancer vaccines are currently being examined in locally advanced oligometastatic prostate cancer. The prostate cancer is biopsied, and the vaccine is developed based on those prostate cancer cells. » Full Article from Cancer Network Genetics & Genomics Researchers Identify Two Genes Responsible for Tumor Progression in Early-Stage Prostate Cancer Researchers have identified two new genes, Bzw2 and Eif5a2, which have been shown to cooperate with the common Pten mutation, speeding the development of prostate cancer. » Full Article from The Institute of Cancer Research Genetics & Genomics Prostate Cancer Epigenetics - From Pathophysiology to Clinical Application Epigenetic biomarkers can be detected in tissue and liquid biopsy samples, sometimes very early in the natural history of prostate cancer and even in precursor lesions, making these markers optimal candidates for screening strategies. However, only a few of these markers show the potential for clinical translation. » Full Article from Nature Treatment When Precision Meets Prostate Cancer: The Rising Role of HIFU Focal Therapy A multi-center prospective study conducted over seven years aimed to learn more about focal therapy as a treatment option that could offer a middle path between active surveillance and a radical prostatectomy or radiation therapy. » Full Article from Nature Outcomes Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection A trial enrolling nearly 1,500 patients demonstrated that extended pelvic lymph node dissection (PLND) provided superior control against metastasis compared to a more limited PLND approach. These findings reinforce the clinical value of extended PLND, which aligns with current NCCN guidelines. » Full Article from UroToday Treatment FDA Accepts NDA for 3-Month Leuprolide Mesylate Formulation for Advanced Prostate Cancer The FDA has accepted a new drug application (NDA) seeking approval for a 3-month formulation of leuprolide. A phase 3 trial showed that 97.9% of patients achieved testosterone suppression to castrate levels, supporting the NDA. The FDA previously approved a 6-month formulation of leuprolide in May 2021. » Full Article from Urology Times ZERO Prostate Cancer provides this informational roundup as a resource; it is not intended to replace medical professionals' or your healthcare team's recommendations. Consult your healthcare team if you have questions about your specific treatment plan. Join the Prostate Cancer Discoveries Digest Email List Don't miss the latest in prostate cancer research! Join ZERO's email list and choose the topics that matter most to you. Enter your email Where did you learn about us?
Welcome to the February 2025 edition of ZERO's Prostate Cancer Discoveries Digest! The latest information on treatment, diagnostics, survivorship, and more has been pulled from the headlines and delivered to your inbox. To ensure you receive this monthly newsletter, be sure to mark ZERO Prostate Cancer as a safe sender in your preferred email client. ZERO Prostate Cancer does not endorse any particular article or finding that may be featured. Genetics & Genomics Moffitt Study Shows How Genomic Tests Could Help Treat Prostate Cancer More Effectively Researchers assessed the Decipher, Oncotype DX Genomic Prostate Score (GPS), and Prolaris genomic tests to understand how results can help patients and doctors make treatment decisions in the early stage setting. The review is part of a larger Department of Veterans Affairs project. » Full Article from Moffitt Cancer Center Diagnostics FDA Fast Tracks 64Cu-SAR-bisPSMA for Biochemically Recurrent Prostate Cancer A second FDA fast-track designation (FTD) was awarded to 64Cu-SAR-bisPSMA for PET imaging of prostate-specific membrane antigen (PSMA)-positive lesions in patients with biochemical recurrence (BCR) of prostate cancer following initial definitive therapy. This novel, advanced imaging led 48% of patients to modify their treatment plan based on the results. » Full Article from Urology Times Genetics & Genomics Classifying FOXA1 Alterations: Implications for Prostate Cancer Prognosis and Treatment Researchers have learned more about the FOXA1 mutation, its higher prevalence in Asian and Black patients, and the classification system's revelation that different FOXA1 mutations may lead to opposing clinical outcomes. » Full Article from UroToday Risk Association Between Prostatic Calculi and Prostate Cancer A new, retrospective study demonstrates an association between prostatic calculi (stones found in the prostate gland) and prostate cancer. » Full Article from ScienceDirect Treatment Vaccine Trials Ongoing in Locally Advanced Oligometastatic Prostate Cancer Prostate cancer vaccines are currently being examined in locally advanced oligometastatic prostate cancer. The prostate cancer is biopsied, and the vaccine is developed based on those prostate cancer cells. » Full Article from Cancer Network Genetics & Genomics Researchers Identify Two Genes Responsible for Tumor Progression in Early-Stage Prostate Cancer Researchers have identified two new genes, Bzw2 and Eif5a2, which have been shown to cooperate with the common Pten mutation, speeding the development of prostate cancer. » Full Article from The Institute of Cancer Research Genetics & Genomics Prostate Cancer Epigenetics - From Pathophysiology to Clinical Application Epigenetic biomarkers can be detected in tissue and liquid biopsy samples, sometimes very early in the natural history of prostate cancer and even in precursor lesions, making these markers optimal candidates for screening strategies. However, only a few of these markers show the potential for clinical translation. » Full Article from Nature Treatment When Precision Meets Prostate Cancer: The Rising Role of HIFU Focal Therapy A multi-center prospective study conducted over seven years aimed to learn more about focal therapy as a treatment option that could offer a middle path between active surveillance and a radical prostatectomy or radiation therapy. » Full Article from Nature Outcomes Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection A trial enrolling nearly 1,500 patients demonstrated that extended pelvic lymph node dissection (PLND) provided superior control against metastasis compared to a more limited PLND approach. These findings reinforce the clinical value of extended PLND, which aligns with current NCCN guidelines. » Full Article from UroToday Treatment FDA Accepts NDA for 3-Month Leuprolide Mesylate Formulation for Advanced Prostate Cancer The FDA has accepted a new drug application (NDA) seeking approval for a 3-month formulation of leuprolide. A phase 3 trial showed that 97.9% of patients achieved testosterone suppression to castrate levels, supporting the NDA. The FDA previously approved a 6-month formulation of leuprolide in May 2021. » Full Article from Urology Times ZERO Prostate Cancer provides this informational roundup as a resource; it is not intended to replace medical professionals' or your healthcare team's recommendations. Consult your healthcare team if you have questions about your specific treatment plan.
Join the Prostate Cancer Discoveries Digest Email List Don't miss the latest in prostate cancer research! Join ZERO's email list and choose the topics that matter most to you. Enter your email Where did you learn about us?
